

# MOLECULAR PHARMACOLOGY

EDITOR: RAYMOND J. DINGLEDINE, *Emory University*

ASSOCIATE EDITORS: P. JEFFREY CONN, *Emory University*  
MICHAEL M. GOTTESMAN, *National Institutes of Health*  
BRIAN K. KOBILKA, *Stanford University*  
KENNETH P. MINNEMAN, *Emory University*  
EDWARD T. MORGAN, *Emory University*

MANAGING EDITOR: WENDY M. WILEY

EDITORIAL ASSISTANT: ESMERALDA GALÁN

## EDITORIAL AND ADVISORY BOARD

NIGEL J. M. BIRDSALL, *National Institute for Medical Research, Mill Hill, United Kingdom*

RANDY D. BLAKELEY, *Vanderbilt University*

JOËL BOCKAERT, *Centre National de la Recherche Scientifique, France*

EDWARD BRESNICK, *University of Massachusetts Medical Center*

JOAN HELLER BROWN, *University of California, San Diego*

MARC G. CARON, *Duke University*

CHARLES CHAVKIN, *University of Washington*

JOHN W. DALY, *National Institutes of Health*

STEVEN K. FISHER, *University of Michigan*

ALFRED G. GILMAN, *University of Texas Southwestern Medical Center, Dallas*

ROBERT I. GLAZER, *Georgetown University*

FRANK J. GONZALEZ, *National Cancer Institute*

F. PETER GUENGERICH, *Vanderbilt University*

JAMES R. HALPERT, *University of Arizona*

HEIDI HAMM, *University of Illinois College of Medicine*

R. ADRON HARRIS, *University of Colorado Health Sciences Center, Denver*

STEPHEN B. HOWELL, *University of California, San Diego*

PAUL A. INSEL, *University of California, San Diego*

KARL H. JAKOBS, *University of Essen, Germany*

ERIC F. JOHNSON, *The Scripps Research Institute*

DENNIS R. KOOP, *Oregon Health Sciences University*

ROBERT J. LEFKOWITZ, *Duke University*

LEE E. LIMBIRD, *Vanderbilt University*

THOMAS M. LINCOLN, *University of Alabama at Birmingham*

JOEL LINDEN, *University of Virginia*

ROBERT L. MACDONALD, *University of Michigan Medical Center*

RONALD P. MASON, *National Institute of Environmental Health Sciences*

MARK L. MAYER, *National Institutes of Health*

JAMES O. MCNAMARA, *Duke University*

RICHARD J. MILLER, *University of Chicago*

GRAEME MILLIGAN, *University of Glasgow, Scotland*

T. J. MURPHY, *Emory University*

CHARLES E. MYERS, JR., *University of Virginia Health Sciences Center*

S. R. NAHORSKI, *University of Leicester, United Kingdom*

DAVID L. NELSON, *Lilly Research Laboratories*

ERIC J. NESTLER, *Yale University*

RICHARD R. NEUBIG, *University of Michigan*

KIM A. NEVE, *Veterans Affairs Medical Center, Portland*

ALLAN B. OKEY, *University of Toronto, Canada*

PAUL ORTIZ DE MONTELLANO, *University of California, San Francisco*

GERRY S. OXFORD, *University of North Carolina at Chapel Hill*

ERIC M. PARKER, *Bristol-Myers Squibb Company*

ALAN POLAND, *University of Wisconsin*

MICHAEL A. ROGAWSKI, *National Institutes of Health*

DARRYLE D. SCHOEPP, *Eli Lilly and Company*

GARY L. STILES, *Duke University*

CATHERINE D. STRADER, *Merck Research Laboratories*

PALMER TAYLOR, *University of California, San Diego*

TODD A. VERDOORN, *Vanderbilt University*

MICHAEL J. WARING, *University of Cambridge, England*

DAVID J. WAXMAN, *Boston University*

GARY L. WESTBROOK, *Vollum Institute*

MICHAEL M. WHITE, *Medical College of Pennsylvania*

STEVEN A. WRIGHTON, *Lilly Research Laboratories*

## BOARD OF PUBLICATIONS TRUSTEES

KENNETH E. MOORE, *Chairman*

KAY A. CROKER, *Executive Officer*

WILLIAM O. BERNDT

D. CRAIG BRATER

DAVID B. BYLUND

WILLIAM A. CATTERALL

MARLENE L. COHEN

RAYMOND J. DINGLEDINE

JOHN A. HARVEY

RAYMOND F. NOVAK

MARCUS M. REIDENBERG

*About the cover:* Depiction of cross-sectioned stereo views of the 5-HT<sub>2A</sub> receptor complexes with ergonovine (cyan) and ergotamine (red). The helical backbones for transmembrane domains 3, 4, 6, and 7 are shown in yellow. A mutagenesis strategy was used to demonstrate the importance of receptor residues F340 and D155 (shown in gray) for docking with the ergoline nucleus. From Choudhary, M. S., N. Sachs, A. Uluer, R. A. Glennon, R. B. Westkaemper, and B. L. Roth. Different ergoline and ergopeptide binding to 5-hydroxytryptamine<sub>2A</sub> receptors: Ergolines require an aromatic residue at position 340 for high affinity binding. *Mol. Pharmacol.* 47:450–457 (1995).

MOLECULAR PHARMACOLOGY

*An International Journal*

VOLUME 48, 1995

EDITOR: RAYMOND J. DINGLEDINE

ASSOCIATE EDITORS: P. JEFFREY CONN  
MICHAEL M. GOTTESMAN  
BRIAN K. KOBILKA  
KENNETH P. MINNEMAN  
EDWARD T. MORGAN

MANAGING EDITOR: WENDY M. WILEY

EDITORIAL ASSISTANT: ESMERALDA GALÁN

EDITORIAL AND ADVISORY BOARD

NIGEL J. M. BIRDSALL  
RANDY D. BLAKELEY  
JOËL BOCKAERT  
EDWARD BRESNICK  
JOAN HELLER BROWN  
MARC G. CARON  
CHARLES CHAVKIN  
JOHN W. DALY  
STEVEN K. FISHER  
ALFRED G. GILMAN  
ROBERT I. GLAZER  
FRANK J. GONZALEZ  
F. PETER GUENGERICH  
JAMES R. HALPERT  
HEIDI HAMM  
R. ADRON HARRIS  
STEPHEN B. HOWELL  
PAUL A. INSEL  
KARL H. JAKOBS  
ERIC F. JOHNSON  
DENNIS R. KOOP  
ROBERT J. LEFKOWITZ  
LEE E. LIMBIRD  
THOMAS M. LINCOLN  
JOEL LINDEN  
ROBERT L. MACDONALD  
RONALD P. MASON

MARK L. MAYER  
JAMES O. MCNAMARA  
RICHARD J. MILLER  
GRAEME MILLIGAN  
T. J. MURPHY  
CHARLES E. MYERS, JR.  
S. R. NAHORSKI  
DAVID L. NELSON  
ERIC J. NESTLER  
RICHARD R. NEUBIG  
KIM A. NEVE  
ALLAN B. OKEY  
PAUL ORTIZ DE MONTELLANO  
GERRY S. OXFORD  
ERIC M. PARKER  
ALAN POLAND  
MICHAEL A. ROGAWSKI  
DARRYLE D. SCHOEPP  
GARY L. STILES  
CATHERINE D. STRADER  
PALMER TAYLOR  
TODD A. VERDOORN  
MICHAEL J. WARING  
DAVID J. WAXMAN  
GARY L. WESTBROOK  
MICHAEL M. WHITE  
STEVEN A. WRIGHTON